Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Steel Dynamics Inc. (STLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Steel Dynamics Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while Steel Dynamics Inc. trades at $244 (market cap $34.81B). The key difference: Steel Dynamics Inc. is far larger — about 12.4× Dyne Therapeutics Inc. Common Stock's market cap, and Steel Dynamics Inc. pays a 0.87% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Steel Dynamics Inc. for 6 Days on average.
| DYN | STLD | |
|---|---|---|
Market Cap | $2.81B | $34.81B |
Volume | 2,195,902 | 766,251 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $282.76 |
52-Week Low | $14.60 | $142.65 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.13B | $38.42B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Steel Dynamics (STLD) trades at $240.63, up 0.62% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, including a 7.83% net income margin and 17.58% ROE, with Q3 2026 earnings expected at $5.41 EPS. Recent news highlights anticipation for the upcoming earnings report on October 19, 2026.
The outlook is positive, supported by analyst consensus of a $271.17 price target and 'Moderate Buy' ratings. Risks include earnings volatility and steel market cyclicality, but revenue growth to $20.5B in 2026 and solid cash flow provide a foundation for potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Steel Dynamics Inc.
Steel Dynamics produces steel, processes recycled metals, and provides steel-fabrication services. Its operations use recycled scrap as a key input and also include aluminum products.
Read more on STLD →
